t
Hemogenyx Pharmaceuticals PLC announced on July 1, 2026, that all 11 resolutions were passed by shareholders at its Annual General Meeting (AGM), held yesterday afternoon. These resolutions included the adoption of annual accounts, re-appointment of directors and auditors, and the granting of authority to allot shares and dis-apply pre-emption rights. Total votes cast for individual resolutions ranged from 20.68% to 22.38% of the company's issued share capital of 6,799,961 ordinary shares as of June 26, 2026.
| Date | 1 Jul 2026 |
| Time | 07:00:03 |
| Category | AGMs and other meetings |
| ID | 4791K |
1 July 2026
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Result of Annual General Meeting
Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held yesterday afternoon, all resolutions were duly passed by shareholders. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.
Proxy Voting Results
|
Ordinary Resolutions |
Votes for |
% of votes cast for |
Votes Against |
% of votes cast against |
Total votes cast |
Total votes cast as % of ISC (1) |
Votes with-held (2) |
|
1. To receive and adopt the Company's annual accounts for the financial year ended 31 December 2025 together with the directors' reports and auditor's report on those accounts |
1,457,300 |
96.22 |
5,966 |
0.39 |
1,514,592 |
22.27 |
16,829 |
|
2. To approve the Directors' Remuneration Report |
1,307,710 |
93.00 |
47,125 |
3.35 |
1,406,161 |
20.68 |
125,260 |
|
3. To re-appoint PKF Littlejohn LLP as auditors |
1,441,698 |
95.73 |
13,011 |
0.86 |
1,506,035 |
22.15 |
25,386 |
|
4. To authorise the Audit Committee to determine the level of the auditor's remuneration |
1,349,329 |
95.78 |
8,150 |
0.58 |
1,408,805 |
20.72 |
122,616 |
|
5. To authorise the re-appointment of Vladislav Sandler |
1,454,810 |
95.68 |
14,398 |
0.95 |
1,520,534 |
22.36 |
10,887 |
|
6. To authorise the re-appointment of Alexis Sandler |
1,371,163 |
91.14 |
81,931 |
5.45 |
1,504,420 |
22.12 |
27,001 |
|
7. To authorise the re-appointment of Sir Marc Feldmann |
1,454,149 |
95.66 |
14,591 |
0.96 |
1,520,066 |
22.35 |
11,355 |
|
8. To authorise the re-appointment of Peter Redmond |
1,224,477 |
81.31 |
230,108 |
15.28 |
1,505,911 |
22.15 |
25,510 |
|
9. To grant the Directors authority to allot and issue shares and grant rights to subscribe for shares in the Company for the purposes of Section 551 of the Act. |
1,242,853 |
87.03 |
133,834 |
9.37 |
1,428,013 |
21.00 |
103,378 |
|
Special Resolutions |
Votes for |
% of votes cast for |
Votes against |
% of votes cast against |
Total votes cast |
Total votes cast as % of ISC (1) |
Votes with-held (2) |
|
10. To dis-apply the statutory rights of pre-emption in respect of the allotment of equity securities for cash under Section 561(1) of the Act. |
1,195,851 |
83.61 |
183,068 |
12.80 |
1,430,245 |
21.03 |
101,176 |
|
11. To authorise the Directors to call a general meeting of the Company, other than an annual general meeting, |
1,409,241 |
92.61 |
61,106 |
4.02 |
1,521,673 |
22.38 |
9,748 |
(1) The Company's issued share capital ("ISC") on 26 June 2026, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 6,799,961 ordinary shares.
(2) A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.
A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Enquiries:
|
Hemogenyx Pharmaceuticals plc |
|
|
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
|
|
Peter Redmond, Director |
|
|
|
|
|
SP Angel Corporate Finance LLP |
Tel: +44 (0)20 3470 0470 |
|
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
|
|
AlbR Capital Limited |
Tel: +44 (0)20 7469 0930 |
|
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.